Find Clinical Trial
Efficacy and safety of Valdoxan® given orally once a day for 24 weeks in patients with Major Depressive Disorder. Open, national, multicentric clinical trial for the evaluation of the antidepressant efficacy and tolerability of ValdoxanR and its additional clinical benefits for depressed patients.
← Back
| Study Phase |
Phase 4 |
| Therapeutic Area |
Neuropsychiatric Diseases |
| Indication | Major Depressive Disorder |
| Sponsor | Servier Slovensko, spol. s.r.o. |
| Active substance/ Medical device |
AGOMELATINE, |
| Active Substance Code | S020098 |
| Protocol Code | IC4-20098-542 |
| EudraCT Code | 2009-010642-57 |
Documents and links
| Scientific publication | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
